Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT07226947
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Smartwatch activity and body composition monitor — DEVICE
    Participants will be provided a smartwatch to monitor their exercise and body composition
  • General guidance on recommended exercise — BEHAVIORAL
    Participants will receive general guidance on recommended exercise

Study Details

The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutide), also known as glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications.

Key Dates

Start date
Nov 24, 2025
Status verified
Dec 2025
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
100 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Smartwatch activity monitor
    Participants will be provided a smartwatch to monitor activity and body composition monitor. They will also have exercise goals set with reminders on the watch.
  • Active Comparator: Usual guidance
    Participants will receive general guidance on recommended exercise

Primary Outcome Measure

Lean mass (kg) [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Diabetes Research CenterBostonMassachusetts02114
Ben O Brenner, BS
[email protected]
617-726-1729
Grace Kuropatkin, BS
[email protected]
617-726-6537
Melissa S Putman, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Diabetes Research Center· Boston, MA

Related Studies